GENSCRIPT BIO (01548) reports that on September 15, 2026, a total of 77,126,000 new shares were issued under the general mandate. As a result, Weihong Jin's long position ratio was passively diluted, while the number of shares held remained unchanged at 801.15 million.
Prior to the dilution, Weihong Jin's long position in GENSCRIPT BIO was 801.15 million shares, representing 36.36%; following the new share issuance, the holding count remained at 801.15 million shares, with the long position ratio falling to 35.13%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments